Overview

Rapid Reinitiation of a Single Tablet Antiretroviral Therapy Using Symtuza® in HIV-1 Infected Treatment-Experienced Patients Off Therapy. (ReSTART)

Status:
Not yet recruiting

Trial end date:
2022-04-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to demonstrate the effectiveness of Symtuza® in a rapid reinitiation model of care in patients with HIV-1 infection and who are treatment-experienced but have been off of antiretroviral therapy (ART) for 12 or more weeks.

Phase:

Phase 4

Details

Lead Sponsor:

The Crofoot Research Center, Inc.

Collaborator:

Janssen Scientific Affairs, LLC

Treatments:

Cobicistat
Darunavir
Emtricitabine
Emtricitabine tenofovir alafenamide
Tenofovir